LBRX

LB Pharmaceuticals Inc

Sep 22 • 02:37PM ET

15.99

+0.11 0.72 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	22.44M	Perf Week	-4.28%
Market Cap	358.93M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	17.37M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	8.43%	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	45.96%	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-7.54%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	20.25 -21.01%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	-211.45% -	ROIC	-	52W Low	14.97 6.85%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.37% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.85	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-2.17%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-2.17%	Rel Volume	0.05	Prev Close	15.88
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	-2.17%	Avg Volume	775.26K	Price	15.99
IPO	Sep 11, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	32,669	Change	0.72%

Sep-12-25 04:27PM

Crunching the numbers on this week's IPO performances

(Yahoo Finance Video)

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	2,000,000	30,000,000	2,686,138	Sep 16 06:09 PM
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	666,666	9,999,990	666,666	Sep 16 06:09 PM
Pontifax Management 4 G.P. (20	10% Owner	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Nussbaum Ran	Director	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Vida Ventures GP III, L.L.C.	10% Owner	Sep 12 '25	Buy	15.00	333,333	4,999,995	880,214	Sep 16 03:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LBRX

LB Pharmaceuticals Inc

Upgrade your FINVIZ experience